HARCP

HEROIN ADDICTION AND
RELATED CLINICAL PROBLEMS

The official journal of
EUROPAD - European Opiate Addiction Treatment Association
WFTOD - World Federation for the Treatment of Opioid Dependence
Editor: Icro Maremmani, MD - Pisa, Italy, EU
Associate Editors:
Thomas Clausen, MD - Oslo, Norway
Pier Paolo Pani, MD - Cagliari, Italy, EU
Marta Torrens, MD - Barcelona, Spain, EU
Statistical Editor:
Mario Miccoli, PhD - Pisa, Italy, EU

HARCP Archives

Browse by article Browse by volume    

Heroin Addiction and Related Clinical Problems: 2024, 26, 42

Extended-release subcutaneous buprenorphine. The 3rd therapeutic revolution

Marc Reisinger

Digital Object Identifier:
https://doi.org/10.62401/2531-4122-2024-42

Summary: Vincent Dole described the discovery of methadone treatment for heroin addicts in 1963 as a "therapeutic revolution". Twenty years later, buprenorphine constituted a second therapeutic revolution. Therapeutic safety and the absence of euphoria give patients a high degree of autonomy, making it possible to bypass the lobby of addiction specialists who were blocking any progress in opioid agonist treatments in France, a country where high-dose buprenorphine was first introduced worldwide. Forty years on, extended-release subcutaneous buprenorphine is emerging as a third therapeutic revolution. Monthly injections make it easier to stop taking the drug, thanks to the elimination of the behavioural reinforcement of daily intake.

Keywords: Extended-release; Buprenorphine; Therapeutic Revolution

 

EUROPAD - European Opiate Addiction Treatment Association
Brussels, Belgium, EU
P. IVA 01681650469 – Codice Fiscale 94002580465 Reserved Area
Tel/Phone: 0584 - 790073 - Email: info@heroinaddictionrelatedclinicalproblems.org
Start of page